Percheron Therapeutics Limited Share Price OTC Markets
Equities
ATHJF
AU0000317281
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.012 USD | -84.00% | -.--% | +20.00% |
03/06 | Percheron Therapeutics Names Chief Medical Advisor | MT |
29/05 | Percheron Therapeutics Completes Enrollment for Phase Two Muscular Dystrophy Trial; Shares Rise 3% | MT |
Sales 2024 * | 3.6M 2.38M 199M | Sales 2025 * | 5.3M 3.51M 293M | Capitalization | 82.94M 54.86M 4.58B |
---|---|---|---|---|---|
Net income 2024 * | -13M -8.6M -718M | Net income 2025 * | -31M -20.5M -1.71B | EV / Sales 2024 * | 20.6 x |
Net cash position 2024 * | 8.92M 5.9M 493M | Net cash position 2025 * | 17.43M 11.53M 963M | EV / Sales 2025 * | 12.4 x |
P/E ratio 2024 * |
-5.87
x | P/E ratio 2025 * |
-2.34
x | Employees | 8 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 83.66% |
1 day | -84.00% | ||
1 month | +20.00% | ||
3 months | +20.00% | ||
6 months | -76.00% | ||
Current year | +20.00% |
Managers | Title | Age | Since |
---|---|---|---|
James Garner
CEO | Chief Executive Officer | - | 08/23/08 |
Phillip Hains
DFI | Director of Finance/CFO | 64 | 09/06/09 |
Anthony Filippis
COO | Chief Operating Officer | - | 01/22/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Phillip Hains
DFI | Director of Finance/CFO | 64 | 09/06/09 |
Ben Price
BRD | Director/Board Member | 68 | 04/21/04 |
James Garner
CEO | Chief Executive Officer | - | 08/23/08 |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+18.15% | 124B | |
+18.02% | 112B | |
+5.07% | 22.94B | |
-12.75% | 22.22B | |
-9.86% | 17.02B | |
-14.97% | 16.88B | |
-39.94% | 16.87B | |
+2.80% | 13.63B | |
+27.39% | 11.61B |
- Stock Market
- Equities
- PER Stock
- ATHJF Stock